A highly sensitive polyclonal antibody-based ELISA for therapeutic monitoring and pharmacokinetic studies of lenalidomide.

J Immunoassay Immunochem

a Department of Pharmaceutical Chemistry, College of Pharmacy , King Saud University, Riyadh , Saudi Arabia.

Published: December 2014

AI Article Synopsis

  • The article introduces a new, highly sensitive ELISA for monitoring lenalidomide (LND), a drug used to treat multiple myeloma.
  • The assay uses a specific polyclonal antibody and LND-BSA conjugate to measure LND levels in plasma, with a detection limit of 0.05 ng/mL and an effective range of 0.1-20 ng/mL.
  • With high precision and the ability to analyze about 200 samples per day, the ELISA is valuable for clinical labs in routine therapeutic monitoring and pharmacokinetic studies of LND.

Article Abstract

This article describes, for the first time, a highly sensitive and specific enzyme-linked immunosorbent assay (ELISA) for therapeutic monitoring and pharmacokinetic studies of lenalidomide (LND), the potent drug for treatment of multiple myeloma (MM). The assay employed a polyclonal antibody that specifically recognizes LND with high affinity, and LND conjugate of bovine serum albumin (LND-BSA) immobilized onto microplate wells as a solid phase. The assay involved a competitive binding reaction between LND, in plasma sample, and the immobilized LND-BSA for the binding sites on a limited amount of the anti-LND antibody. The assay limit of detection was 0.05 ng/mL and the effective working range at relative standard deviations (RSD) of ≤5% was 0.1-20 ng/mL. Analytical recovery of LND from spiked plasma was 100.98 ± 3.05. The precisions of the assay were satisfactory; RSD was 2.96-6.67% and 4.46-7.14%, for the intra- and inter-assay precision, respectively. The procedure is convenient, and one can analyze ∼200 samples per working day, facilitating the processing of large-number batch of samples in clinical laboratories. The proposed ELISA has a great value in routine analysis of LND for its therapeutic monitoring and pharmacokinetic studies.

Download full-text PDF

Source
http://dx.doi.org/10.1080/15321819.2013.824898DOI Listing

Publication Analysis

Top Keywords

therapeutic monitoring
12
monitoring pharmacokinetic
12
pharmacokinetic studies
12
highly sensitive
8
elisa therapeutic
8
studies lenalidomide
8
lnd
6
assay
5
sensitive polyclonal
4
polyclonal antibody-based
4

Similar Publications

Background: Thyroid nodules classified cytologically as low-risk indeterminate lesions (TIR3A) on fine-needle aspiration biopsy (FNAB) present a clinical challenge due to their uncertain malignancy risk. This single-center study aimed to evaluate the natural history of TIR3A nodules.

Materials And Methods: FNABs performed between July 2017 and December 2019 were retrospectively retrieved and patients with TIR3A nodules were evaluated at baseline and throughout a follow-up based on ultrasound (US) parameters and clinical data.

View Article and Find Full Text PDF

Background: Psoriasis is an inflammatory disease primarily treated through molecular-targeted therapies. However, emerging evidence suggests that dietary interventions may also play a role in managing inflammation associated with this condition. The Mediterranean diet (MedDiet), prevalent in southern European countries, has been widely recognized for its ability to reduce cardiovascular mortality, largely due to its anti-inflammatory properties.

View Article and Find Full Text PDF

Background And Objectives: Cognitive deficits represent a major long-term complication of anti-leucine-rich, glioma-inactivated 1 encephalitis (LGI1-E). Although severely affecting patient outcomes, the structural brain changes underlying these deficits remain poorly understood. In this study, we hypothesized a link between white matter (WM) networks and cognitive outcomes in LGI1-E.

View Article and Find Full Text PDF

This review aimed to identify the impact of the ECHO® model on monitoring people diagnosed with diabetes mellitus. It followed the Joanna Briggs Institute and the PRISMA-ScR Checklist. The search was conducted in the Cochrane Library, Embase, Virtual Health Library, PubMed/MEDLINE, Scopus, and Web of Science databases.

View Article and Find Full Text PDF

Clinical, Laboratory, and Trichoscopic Features of Pediatric Androgenetic Alopecia.

Cutis

December 2024

Drs. Lu, Du, Zhao, and Fan and Lingbo Bi, Chaofan Wang, and Yunbu Ding are from the Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, China. Yige Fan is from the Mayo Clinic, Rochester, Minnesota.

In this retrospective study, we analyzed the prevalence and impact of pediatric androgenetic alopecia (AGA). Over a 14-year period, 133 pediatric patients were evaluated, with manifestations of AGA appearing as early as age 10 years. The analysis included factors such as body mass index (BMI), family history of AGA, comorbidities, laboratory results, and patterns of hair loss.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!